Making the switch
from RX to OTC

Differin

The challenge

There's good news if you're one of the 50 million Americans suffering from acne, Differin®, a retinoid that was previously available by prescription only, is now the first and only prescription-strength acne medication to receive over-the-counter approval from the U.S. Food and Drug Administration, and the first new active ingredient to the acne category in over 30 years!

Galderma, Differin’s parent company, turned to Lippe Taylor to create awareness for the FDA approval of the Rx to OTC switch. We not only had to handle their press materials that announced the FDA approval, but make a splash for the brand among potential retailers, key influencers, HCP/PCPs and the media in the process!

How we cracked the code

In addition to traditional media outreach, what really elevated our results was our team of key physicians. We tapped into Lippe Taylor’s strong network of KOLS, PCPs & HCPs - all of whom were provided key messages and press release information. This effort created a ton of awareness and excitement in the media, as well as within the physicians own practices and patient bases.

ROI

Initial media outreach around the FDA approval news of Differin® generated a total of 488,396,561 media impressions with announcements in top health, trade, and consumer websites including The Dermatologist, Chain Drug Review, Drugs.com, Health.com, Refinery29, Allure.com, Yahoo, Seventeen.com, Elle.com, Shape.com, TeenVogue.com & more!

Current case study

Differin